Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571463 | 0.80 | GPR35 (0.47) | MEN1KMT2AGAATHRBMAPT | |
| SCHEMBL1191637 | 0.80 | GPR35 (0.47) | MEN1KMT2AGAATHRBMAPT | |
| SCHEMBL3688848 | 0.80 | MAPT (0.47) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL18486948 | 0.78 | KMT2A (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL8561095 | 0.78 | MEN1 (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL203785 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL30622636 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL414810 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL28802588 | 0.77 | MEN1 (0.41) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL5126783 | 0.77 | PKM (0.42) | MEN1KMT2AUSP2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1660842-A | Preparation of 4-hydroxy-3-nitro-2(1h)-pyridone from 2-hydroxy-3-cyano-4-methoxypyridine | AVENTIS PHARMA INC (US) | 2005-08-31 | — | — | CN | claimed |
| CN-1191251-C | Intermediate for preparing cyclopentane formamide compound and preparation method thereof | AVENTIS PHARMACEUTICAL CO (US) | 2005-03-02 | — | — | CN | claimed |
| CN-1394859-A | Intermediate for preparing cyclopentane formamide compound and preparation method thereof | AVENTIS PHARMACEUTICAL CO (US) | 2003-02-05 | — | — | CN | claimed |
| CN-1090630-C | Preparation method of [1S- [1a,2b,3b,4a ] ] -4- [7- [ [1- (3-chloro-2-thienyl) methyl ] propyl ] amino ] -3H-imidazo [4, 5-b ] pyridin-3-yl ] -N-ethyl-2, 3-dihydroxycyclopentanecarboxamide | AVENTIS PHARMACEUTICAL INC (US) | 2002-09-11 | — | — | CN | claimed |
| CN-1240445-A | Preparation method of [ 1S- [1a,2b,3b,4a ] ] -4- [ 7- [ [ 1- (3-chloro-2-thienyl) methyl ] propyl ] amino-3H-imidazo [4, 5-b ] pyridin-3-yl ] -N-ethyl-2, 3-dihydroxycyclopentanecarboxamide | RHONE POULENC RORER PHARMA (US) | 2000-01-05 | — | — | CN | claimed |
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | disclosed |
| EP-1569936-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-09-07 | — | — | EP | disclosed |
| CN-1660842-A | Preparation of 4-hydroxy-3-nitro-2(1h)-pyridone from 2-hydroxy-3-cyano-4-methoxypyridine | AVENTIS PHARMA INC (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1191251-C | Intermediate for preparing cyclopentane formamide compound and preparation method thereof | AVENTIS PHARMACEUTICAL CO (US) | 2005-03-02 | — | — | CN | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
| CN-1394859-A | Intermediate for preparing cyclopentane formamide compound and preparation method thereof | AVENTIS PHARMACEUTICAL CO (US) | 2003-02-05 | — | — | CN | disclosed |
| CN-1090630-C | Preparation method of [1S- [1a,2b,3b,4a ] ] -4- [7- [ [1- (3-chloro-2-thienyl) methyl ] propyl ] amino ] -3H-imidazo [4, 5-b ] pyridin-3-yl ] -N-ethyl-2, 3-dihydroxycyclopentanecarboxamide | AVENTIS PHARMACEUTICAL INC (US) | 2002-09-11 | — | — | CN | disclosed |
| CN-1240445-A | Preparation method of [ 1S- [1a,2b,3b,4a ] ] -4- [ 7- [ [ 1- (3-chloro-2-thienyl) methyl ] propyl ] amino-3H-imidazo [4, 5-b ] pyridin-3-yl ] -N-ethyl-2, 3-dihydroxycyclopentanecarboxamide | RHONE POULENC RORER PHARMA (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | MEN1 3264/4885KMT2A 2970/4885USP2 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.